Next-gen Bispecific Compounds & Innovative Therapies | Biohaven

DEVELOPING NEXT-GENERATION BISPECIFIC COMPOUNDS AND INNOVATIVE THERAPIES

Biohaven is developing drug candidates based on its proprietary, next-generation bispecific technology platforms and other innovative approaches. These bispecific platforms are modular in design to enable rapid generation of novel therapies for the treatment of diseases with high unmet medical needs. The other innovative therapies are comprised of novel approaches with potential to be first-in-class or best-in-class treatments.

ION CHANNEL

Kv7

Our Kv7 potassium channel platform supports the development of small molecule treatments within our portfolio. The Kv7 platform offers therapeutic opportunity in multiple disease states.

TRPM3

In addition to BHV-2100, we are optimizing other lead compounds for TRPM3-mediated disorders of the peripheral and central nervous systems.

DEGRADERS

MoDE™ and TRAP™

MoDE and TRAP Extracellular Protein Degrader Platform is a proprietary drug development platform for small molecule therapies to address a broad range of antibody-mediated diseases.

NEXT-GEN ADCs

MATE™

Our highly differentiated Antibody Drug Conjugates (ADCs) have the potential to broaden therapeutic margin, increase time on treatment, and improve efficacy for people living with cancer. Biohaven’s proprietary MATE platform technology focuses on novel, single-step conjugation chemistry, with the potential to be superior to the current industry standard.